Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDH17/GUCY2C CAR-T in Advanced Colorectal Cancer
NCT07152210Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CDH17/GUCY2C CAR-T in colorectal cancer (CRC), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Evaluation of Safety at 1 year and Effectiveness evaluation at 1 year. Planned start Dec 2024; status: withdrawn.
02
Drugs
CDH17/GUCY2C CAR-T
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07152210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152210.